Emerging drugs for migraine treatment

Expert Opinion on Emerging Drugs

Volumn 20, Issue 1, 2015, Pages 137-147

  Giamberardino, Maria Adele ^a   Martelletti, Paolo ^b  

^a UNIVERSITY OF CHIETI   (Italy)

^b SAPIENZA UNIVERSITY OF ROME   (Italy)

Author keywords

Acid sensing ion channels; Acute and preventative treatment; Antibodies against calcitonin gene related peptide; Calcitonin gene related peptide receptor antagonists; Migraine; Nitric oxide; Selective 5 hydroxytryptamine1F receptor agonists; Transient receptor potential channels

Indexed keywords

ACID SENSING ION CHANNEL; CALCITONIN GENE RELATED PEPTIDE; CALCITONIN GENE RELATED PEPTIDE RECEPTOR ANTAGONIST; MONOCLONAL ANTIBODY; NITRIC OXIDE; NONSTEROID ANTIINFLAMMATORY AGENT; SEROTONIN 1F RECEPTOR; SEROTONIN AGONIST; TRANSIENT RECEPTOR POTENTIAL CHANNEL; TRIPTAN DERIVATIVE; CALCITONIN GENE RELATED PEPTIDE RECEPTOR;

ANALGESIA; CHRONICITY; COMORBIDITY; DRUG MECHANISM; DRUG TARGETING; HUMAN; MIGRAINE; REVIEW; SYNAPTIC TRANSMISSION; ANIMAL; ANTAGONISTS AND INHIBITORS; CHRONIC DISEASE; DISEASE COURSE; DRUG DESIGN; MIGRAINE DISORDERS; MOLECULARLY TARGETED THERAPY; PATHOPHYSIOLOGY; TREATMENT OUTCOME;

ANIMALS; CHRONIC DISEASE; DISEASE PROGRESSION; DRUG DESIGN; HUMANS; MIGRAINE DISORDERS; MOLECULAR TARGETED THERAPY; RECEPTORS, CALCITONIN GENE-RELATED PEPTIDE; TREATMENT OUTCOME;

EID: 84923309625     PISSN: 14728214     EISSN: 17447623     Source Type: Journal    
DOI: 10.1517/14728214.2015.999040     Document Type: Review

References (92)

1. Rasmussen BK, Olesen J. Migraine with aura and migraine without aura: an epidemiological study. Cephalalgia 1992; 12: 221-8
2. Stewart WF, Lipton RB, Celentano DD, Reed ML. Prevalence of migraine headache in the United States. Relation to age, income, race, and other sociodemographic factors. JAMA 1992; 267: 64-9
3. Martelletti P, Birbeck GL, Katsarava Z, et al. The global burden of disease survey 2010, lifting the burden and thinking outside-the-box on headache disorders. J Headache Pain 2013; 14: 13
4. Murray CJ, Lopez AD. Measuring the global burden of disease. N Engl J Med 2013; 369: 448-57
5. Smitherman TA, Burch R, Sheikh H, Loder E. The prevalence, impact, and treatment of migraine and severe headaches in the United States: a review of statistics from national surveillance studies. Headache 2013; 53 (3): 427-36
6. Blumenfeld AM, Varon SF, Wilcox TK, et al. Disability, HRQoL and resource use among chronic and episodic migraineurs: results from the International Burden of Migraine Study (IBMS). Cephalalgia 2011; 31: 301-15
7. Lipton RB, Bigal ME. Migraine: epidemiology, impact, and risk factors for progression. Headache 2005; 45: S3-13
8. Headache Classification Committee of the International Headache Society (IHS). The international classification of headache disorders, 3rd edition (beta version). Cephalalgia 2013; 33: 629-808
9. Lipton RB. Chronic migraine, classification, differential diagnosis, and epidemiology. Headache 2011; 51 (Suppl 2): 77-83
10. Affaitati G, Fabrizio A, Savini A, et al. A randomized, controlled study comparing a lidocaine patch, a placebo patch, and anesthetic injection for treatment of trigger points in patients with myofascial pain syndrome: evaluation of pain and somatic pain thresholds. Clin Ther 2009; 31: 705-20
11. Giamberardino MA, Affaitati G, Fabrizio A, Costantini R. Myofascial pain syndromes and their evaluation. Best Pract Res Clin Rheumatol 2011; 25: 185-98
12. Giamberardino MA, Tafuri E, Savini A, et al. Contribution of myofascial trigger points to migraine symptoms. J Pain 2007; 8: 869-78
13. Lionetto L, Negro A, Palmisani S, et al. Emerging treatment for chronic migraine and refractory chronic migraine. Expert Opin Emerg Drugs 2012; 17: 393-406
14. Martelletti P. The therapeutic armamentarium in migraine is quite elderly. Expert Opin Drug Metab Toxicol 2014; 1-3; Epub ahead of print
15. Silberstein SD. Emerging target-based paradigms to prevent and treat migraine. Clin Pharmacol Ther 2013; 93: 78-85
16. Akerman S, Holland PR, Goadsby PJ. Diencephalic and brainstem mechanisms in migraine. Nat Rev Neurosci 2011; 12: 570-84
17. Goadsby PJ. The vascular theory of migraine-a great story wrecked by the facts. Brain 2009; 132 (Pt 1): 6-7
18. Hoffmann J, Goadsby PJ. Emerging targets in migraine. CNS Drugs 2014; 28: 11-17
19. Sabato D, Lionetto L, Martelletti P. The therapeutic potential of novel antimigraine acute therapies. Expert Opin Investig Drugs 2014; 1-4; Epub ahead of print
20. Belvis R, Mas N, Aceituno A. Migraine attack treatment: a tailor-made suit, not one size fits all. Recent Pat CNS Drug Discov 2014; 9: 26-40
21. Negro A, Napoletano F, Lionetto L, et al. Treatment of menstrual migraine: utility of control of related mood disturbances. Expert Rev Neurother 2014; 14: 493-502
22. Vollbracht S, Rapoport AM. The pipeline in headache therapy. CNS Drugs 2013; 27: 717-29
23. Goadsby PJ, Lipton RB, Ferrari MD. Migraine-current understanding and treatment. N Engl J Med 2002; 346: 257-70
24. Rizzoli PB. Emerging therapeutic options for acute migraine: focus on the potential of lasmiditan. Neuropsychiatr Dis Treat 2014; 10: 547-52
25. Labruijere S, Ibrahimi K, Chan KY, Maassenvandenbrink A. Discovery techniques for calcitonin gene-related peptide receptor antagonists for potential antimigraine therapies. Expert Opin Drug Discov 2013; 8: 1309-23
26. Tana C, Santilli F, Martelletti P, et al. Correlation between Migraine Severity and Cholesterol Levels. Pain Pract 2014; doi: 10.1111/papr.12229. [Epub ahead of print]
27. Tana C, Tafuri E, Tana M, et al. New insights into the cardiovascular risk of migraine and the role of white matter hyperintensities: is gold all that glitters? J Headache Pain 2013; 14 (1): 9
28. Silberstein SD, Stirpe JC. COX inhibitors for the treatment of migraine. Expert Opin Pharmacother 2014; 15: 1863-74
29. Brain SD, Grant AD. Vascular actions of calcitonin gene-related peptide and adrenomedullin. Physiol Rev 2004; 84: 903-34
30. Edvinsson L, Gulbenkian S, Barroso CP, et al. Innervation of the human middle meningeal artery: immunohistochemistry, ultrastructure, and role of endothelium for vasomotility. Peptides 1998; 19: 1213-25
31. Eftekhari S, Salvatore CA, Calamari A, et al. Differential distribution of calcitonin gene-related peptide and its receptor components in the human trigeminal ganglion. Neuroscience 2010; 169: 683-96
32. Hokfelt T, Arvidsson U, Ceccatelli S, et al. Calcitonin gene-related peptide in the brain, spinal cord, and some peripheral systems. Ann N Y Acad Sci 1992; 30: 119-34
33. van Rossum D, Hanisch UK, Quirion R. Neuroanatomical localization, pharmacological characterization and functions of CGRP, related peptides and their receptors. Neurosci Biobehav Rev 1997; 21: 649-78
34. Goadsby PJ, Edvinsson L. The trigeminovascular system and migraine: studies characterizing cerebrovascular and neuropeptide changes seen in humans and cats. Ann Neurol 1993; 33: 48-56
35. Goadsby PJ, Edvinsson L, Ekman R. Release of vasoactive peptides in the extracerebral circulation of humans and the cat during activation of the trigeminovascular system. Ann Neurol 1988; 23: 193-6
36. Goadsby PJ, Edvinsson L, Ekman R. Vasoactive peptide release in the extracerebral circulation of humans during migraine headache. Ann Neurol 1990; 28: 183-7
37. Lassen LH, Haderslev PA, Jacobsen VB, et al. CGRP may play a causative role in migraine. Cephalalgia 2002; 22: 54-61
38. Storer RJ, Akerman S, Goadsby PJ. Calcitonin gene-related peptide (CGRP) modulates nociceptive trigeminovascular transmission in the cat. Br J Pharmacol 2004; 142: 1171-81
39. Goadsby PJ. Recent advances in understanding migraine mechanisms, molecules and therapeutics. Trends Mol Med 2007; 13: 39-44
40. Edvinsson L, Warfvinge K. CGRP receptor antagonism and migraine therapy. Curr Protein Pept Sci 2013; 14: 386-92
41. Vécsei L, Szok D, Csáti A, Tajti J. CGRP antagonists and antibodies for the treatment of migraine. Expert Opin Investig Drugs 2015; 24: 31-41
42. Nelson DL, Phebus LA, Johnson KW, et al. Preclinical pharmacological profile of the selective 5-HT1F receptor agonist lasmiditan. Cephalalgia 2010; 30: 1159-69
43. Olesen J. 5-Hydroxyptryptamine 1F (5-HT1F) receptor agonism. A possible new treatment principle for acute migraine attacks. Cephalalgia 2010; 30: 1157-8
44. Ramadan NM. The link between glutamate and migraine. CNS Spectr 2003; 8: 446-9
45. Tfelt-Hansen PC, Pihl T, Hougaard A, Mitsikostas DD. Drugs targeting 5-hydroxytryptamine receptors in acute treatments of migraine attacks. A review of new drugs and new administration forms of established drugs. Expert Opin Investig Drugs 2014; 23: 375-85
46. Deval E, Gasull X, Noel J, et al. Acid-sensing ion channels (ASICs): pharmacology and implication in pain. Pharmacol Ther 2010; 128: 549-58
47. Hadjikhani N, Sanchez Del Rio M, Wu O, et al. Mechanisms of migraine aura revealed by functional MRI in human visual cortex. Proc Natl Acad Sci USA 2001; 98: 4687-92
48. Dussor G, Yan J, Xie JY, et al. Targeting TRP channels for novel migraine therapeutics. ACS Chem Neurosci 2014; 5: 1085-96
49. Kelman L. The triggers or precipitants of the acute migraine attack. Cephalalgia 2007; 27: 394-402
50. Benemei S, Fusi C, Trevisan G, Geppetti P. The TRPA1 channel in migraine mechanism and treatment. Br J Pharmacol 2014; 171: 2552-67
51. Nicoletti P, Trevisani M, Manconi M, et al. Ethanol causes neurogenic vasodilation by TRPV1 activation and CGRP release in the trigeminovascular system of the guinea pig. Cephalalgia 2008; 28: 9-17
52. Geppetti P, Nassini R, Materazzi S, Benemei S. The concept of neurogenic inflammation. BJU Int 2008; 101: 2-6
53. Lima AM, Sapienza GB, Giraud Vde O, Fragoso YD. Odors as triggering and worsening factors for migraine in men. Arq Neuropsiquiatr 2011; 69: 324-7
54. Strassman AM, Levy D. Response properties of dural nociceptors in relation to headache. J Neurophysiol 2006; 95: 1298-306
55. Burstein R, Jakubowski M, Garcia-Nicas E, et al. Thalamic sensitization transforms localized pain into widespread allodynia. Ann Neurol 2010; 68: 81-91
56. Noseda R, Burstein R. Migraine pathophysiology: anatomy of the trigeminovascular pathway and associated neurological symptoms, CSD, sensitization and modulation of pain. Pain 2013; 154 (Suppl 1): S44-53
57. De Col R, Koulchitsky SV, Messlinger KB. Nitric oxide synthase inhibition lowers activity of neurons with meningeal input in the rat spinal trigeminal nucleus. Neuroreport 2003; 14: 229-32
58. Tassorelli C, Joseph SA. Systemic nitroglycerin induces Fos immunoreactivity in brainstem and forebrain structures of the rat. Brain Res 1995; 682: 167-81
59. Burstein R, Cutrer MF, Yarnitsky D. The development of cutaneous allodynia during a migraine attack clinical evidence for the sequential recruitment of spinal and supraspinal nociceptive neurons in migraine. Brain 2000; 123 (Pt 8): 1703-9
60. Burstein R, Yarnitsky D, Goor-Aryeh I, et al. An association between migraine and cutaneous allodynia. Ann Neurol 2000; 47: 614-24
61. Lin Q, Palecek J, Paleckova V, et al. Nitric oxide mediates the central sensitization of primate spinothalamic tract neurons. J Neurophysiol 1999; 81 (3): 1075-85
62. Thomsen LL, Olesen J. Nitric oxide in primary headaches. Curr Opin Neurol 2001; 14: 315-21
63. Olesen J, Diener HC, Husstedt IW, et al. Calcitonin gene-related peptide receptor antagonist BIBN 4096 BS for the acute treatment of migraine. N Engl J Med 2004; 350 (11): 1104-10
64. Connor KM, Shapiro RE, Diener HC, et al. Randomized, controlled trial of telcagepant for the acute treatment of migraine. Neurology 2009; 73 (12): 970-7
65. Ho TW, Ferrari MD, Dodick DW, et al. Efficacy and tolerability of MK-0974 (telcagepant), a new oral antagonist of calcitonin gene-related peptide receptor, compared with zolmitriptan for acute migraine: a randomised, placebocontrolled, parallel-treatment trial. Lancet 2008; 372 (9656): 2115-23
66. Ho TW, Mannix LK, Fan X, et al. Randomized controlled trial of an oral CGRP receptor antagonist, MK-0974, in acute treatment of migraine. Neurology 2008; 70 (16): 1304-12
67. Connor KM, Aurora SK, Loeys T, et al. Long-term tolerability of telcagepant for acute treatment of migraine in a randomized trial. Headache 2011; 51: 73-84
68. Han TH, Blanchard RL, Palcza J, et al. Single-and multiple-dose pharmacokinetics and tolerability of telcagepant, an oral calcitonin generelated peptide receptor antagonist, in adults. J Clin Pharmacol 2010; 50: 1367-76
69. Ho TW, Connor KM, Zhang Y, et al. Randomized controlled trial of the CGRP receptor antagonist telcagepant for migraine prevention. Neurology 2014; 83: 958-66
70. Hewitt DJ, Aurora SK, Dodick DW, et al. Randomized controlled trial of the CGRP receptor antagonist MK-3207 in the acute treatment of migraine. Cephalalgia 2011; 31 (6): 712-22
71. Diener HC, Barbanti P, Dahlof C, et al. BI 44370 TA, an oral CGRP antagonist for the treatment of acute migraine attacks: results from a phase II study. Cephalalgia 2011; 31: 573-84
72. Bigal ME. BMS-927711 for the acute treatment of migraine. Cephalalgia 2014; 34: 90-2
73. Marcus R, Goadsby PJ, Dodick D, et al. BMS-927711 for the acute treatment of migraine: a double-blind, randomized, placebo controlled, dose-ranging trial. Cephalalgia 2014; 34: 114-25
74. Bigal ME, Walter S. Monoclonal antibodies for migraine: preventing calcitonin gene-related peptide activity. CNS Drugs 2014; 28: 389-99
75. Zhu DXD, Zhang J, Zhou L, et al. A human CGRP receptor antagonist antibody, AA95, is effective in inhibiting capsaicin-induced increase in dermal blood flow in cynomolgus monkeys. Headache 2012; 52: 871-2
76. Zeller J, Poulsen KT, Sutton JE, et al. CGRP function-blocking antibodies inhibit neurogenic vasodilatation without affecting heart rate or arterial blood pressure in the rat. Br J Pharmacol 2008; 155: 1093-103
77. Dodick DW, Goadsby PJ, Spierings EL, et al. Safety and efficacy of LY2951742, a monoclonal antibody to calcitonin gene-related peptide, for the prevention of migraine: a phase 2, randomised, double-blind, placebo-controlled study. Lancet Neurol 2014; 13: 885-92
78. Dodick DW, Goadsby PJ, Silberstein SD, et al. Safety and efficacy of ALD403, an antibody to calcitonin gene-related peptide, for the prevention of frequent episodic migraine: a randomised, double-blind, placebocontrolled, exploratory phase 2 trial. Lancet Neurol 2014; 13: 1100-7
79. Walter S, Alibhoy A, Escandon R, Bigal ME. Evaluation of cardiovascular parameters in cynomolgus monkeys following IV administration of LBR-101, a monoclonal antibody against calcitonin gene-related peptide. MAbs 2014; 6: 871-8
80. Bigal M, Escandon R, Bronson M, et al. Safety and tolerability of LBR-101, a humanized monoclonal antibody that blocks the binding of CGRP to its receptor: results of the Phase 1 program. Cephalalgia 2013; 34: 483-92
81. Bigal ME, Walter S, Bronson M, et al. Cardiovascular and hemodynamic parameters in women following prolonged CGRP inhibition using LBR-101, a monoclonal antibody against CGRP. Cephalalgia 2014; 34: 968-76
82. Goldstein DJ, Roon KI, Offen WW, et al. Selective serotonin 1F (5-HT[1F]) receptor agonist LY334370 for acute migraine: a randomised controlled trial. Lancet 2001; 358: 1230-4
83. Ferrari MD, Farkkila M, Reuter U, et al. Acute treatment of migraine with the selective 5-HT1F receptor agonist lasmiditan-a randomised proof-of-concept trial. Cephalalgia 2010; 30: 1170-8
84. Farkkila M, Diener HC, Geraud G, et al. Efficacy and tolerability of lasmiditan, an oral 5-HT (1F) receptor agonist, for the acute treatment of migraine: a Phase II randomised, placebo-controlled, parallel-group, dose-ranging study. Lancet Neurol 2012; 11: 405-13
85. Holland PR, Akerman S, Andreou AP, et al. Acid-sensing ion channel 1: a novel therapeutic target for migraine with aura. Ann Neurol 2012; 72: 559-63
86. Materazzi S, Benemei S, Fusi C, et al. Parthenolide inhibits nociception and neurogenic vasodilatation in the trigeminovascular system by targeting TRPA1 channel. Pain 2013; 154: 2750-8
87. Lassen LH, Ashina M, Christiansen I, et al. Nitric oxide synthase inhibition in migraine. Lancet 1997; 349: 401-2
88. Olesen J. Nitric oxide-related drug targets in headache. Neurotherapeutics 2010; 7: 183-90
89. Hoivik HO, Laurijssens BE, Harnisch LO, et al. Lack of efficacy of the selective iNOS inhibitor GW274150 in prophylaxis of migraine headache. Cephalalgia 2010; 30: 1458-67
90. Høye KLB, Harnisch LO, Twomey CK, et al. Efficacy and tolerability of the iNOS inhibitor GW274150 administered up to 120 mg daily for 12 weeks in the prophylactic treatment of migraine. Cephalalgia 2009; 29: 132
91. Palmer JE, Guillard FL, Laurijssens BE, et al. A randomised, single-blind, placebo-controlled, adaptive clinical trial of GW274150, a selective iNOS inhibitor, in the treatment of acute migraine. Cephalalgia 2009; 29: 124
92. Bhatt DK, Gupta S, Jansen-Olesen I, et al. NXN-188, a selective nNOS inhibitor and a 5-HT1B/1D receptor agonist, inhibits CGRP release in preclinical migraine models. Cephalalgia 2013; 33: 87-100